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Abstract
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of vasculitis associated with asthma and eosinophilia.
Endothelial dysfunction has been well documented in other types of vasculitis but not in EGPA. Thirty patients (10 men and
20 women) diagnosed with EGPA and remaining in a remission, and 58 controls (24 men and 34 women) matched for age, sex,
and body mass index, were enrolled in the study. We assessed each participants for typical risk factors of cardiovascular diseases
and measured serum levels of vascular cell adhesion molecule-1 (VCAM-1), interleukin 6 (IL-6), and thrombomodulin. We also
measured flow-mediated dilatation (FMD) of the brachial artery and intima-media thickness (IMT) of the common carotid artery
using ultrasonography. Patients with EGPA had 20% higher serum level of VCAM-1 (p < 0.001) and 41.9% of thrombomodulin
(p < 0.001). They also had 38.8% lower relative increase of FMD (FMD%) (p < 0.001), indicating endothelial dysfunction. These
differences remained significant also after adjustment for potential confounders. Laboratory and ultrasonographic parameters of
endothelial injury were correlated to the markers of inflammation and impaired kidney function. Determinants of lower FMD%
in a simple regressionmodel were pack-years of smoking (β = − 0.3 [95% confidence interval (CI) − 0.5 to − 0.1]), serum level of
IL-6 (β = − 0.36 [95% CI − 0.62 to − 0.1]), and thrombomodulin (β = − 0.34 [95% CI − 0.6 to − 0.08]). EGPA patients are
characterized by inflammatory endothelial injury that is likely related to the pathogenesis of the disease. Proper immunosup-
pressive treatment is the best method to prevent atherosclerosis and future cardiovascular events, the patients may also benefit
from additional preventive interventions.
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Introduction
Eosinophilic granulomatosis with polyangiitis (EGPA, for-
merly named Churg-Strauss syndrome) is a rare disease with
a prevalence that ranges from 10.7 to 13 cases per million [1].
Although EGPA is considered to be an anti-neutrophil cyto-
plasmic antibody (ANCA)-associated vasculitis (AAV), a sig-
nificant ANCA serum concentration is found only in approx-
imately 40% of patients, usually in the perinuclear immuno-
fluorescence pattern (p-ANCA) [2]. Tissues affected show
necrotizing vasculitis in EGPA patients who are ANCA-
positive while in those without ANCAs, the vessel walls are
infiltrated mainly by eosinophils [3]. Due to the lack of spec-
ificity of antibodies, diagnosis of EGPA is generally made
clinically. However, a biopsy of the affected organ may reveal
some typical features, such as the extravascular granulomas,
small- and medium-sized vessels vasculitis, and the eosino-
philic infiltrates [1]. In contrast to the other types of AAV,
patients with EGPA characteristically suffer from asthma with
eosinophilia, the hallmark of this disease, occurring in over
95% of individuals [4, 5]. Other symptoms include nasal
polyps, lung infiltrates, and mononeuritis multiplex [6]. As
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EGPA is a systemic disease, clinical manifestation can
be highly variable and patients with EGPA may also
present with gastrointestinal, neurological, and cardio-
vascular symptoms [7–9].
In ANCA-positive AAV, vascular damage is caused by the
stimulation of neutrophils by antibodies, their subsequent ad-
hesion and migration to endothelium, release of proteolytic
enzymes, and proinflammatory cytokines, leading to endothe-
lial cell damage [3]. In the 60% of EGPA patients who are
ANCA-negative, the exact pathology in unknown, but it is
suspected to be related to impaired eosinophil function. A
few studies have found endothelial damage and progression
of atherosclerosis in AAV patients [10–13] but the signifi-
cance of their results is limited by small sample size. We have
found no such investigation specifically concerning patients
with EGPA in the literature.
In this study, we sought to evaluate the endothelium func-
tion in subjects with EGPA. We performed a comprehensive
analysis using laboratory and ultrasonographic tests. The in-
flammatory state was estimated by interleukin-6 (IL-6) serum
level, while injury of endothelium was assessed by serum
concentration of vascular cell adhesion molecule-1 (VCAM-
1) and thrombomodulin. Endothelial function was determined
by ultrasound measurements of flow-mediated dilatation
(FMD) of a brachial artery. This method enables estimation
of the endothelium’s response to shear, releasing nitric oxide
and dilatation. Progression of atherosclerosis was assessed by




Our study is based on the case-control observational format.
We received approval from the Bioethics Committee of
Jagiellonian University Medical College. All study partici-
pants were given a thorough explanation of the methodology
and safety protocol before giving written consent for their
inclusion in the study.
The case group was made up of 30 patients with EGPA—
20women and 10men. They were recruited in the period from
2014 to 2017 at the Department of Allergy and Clinical
Immunology at the University Hospital in Cracow, a diagnos-
tics and treatment center for vasculitis in southern Poland. The
patients were all previously diagnosed with EGPA based on
the criteria of the American College of Rheumatology [14].
The activity of the disease was measured using the
Birmingham Vasculitis Activity Score (BVAS) [15]. We in-
cluded only patients remaining in a remission of the disease.
Remission was defined as an absence of disease activity at-
tributable to active disease qualified by the need for ongoing
stable maintenance immunosuppressive therapy [16]. Patients
were excluded from the study if they also had angina pectoris,
congestive heart failure, uncontrolled hypertension, liver fail-
ure, or cancer.
The control group was made up of 58 healthy individ-
uals—34 women and 24 men matched to the EGPA group
by gender, age, and body mass index [BMI]. Exclusion
criteria were any manifestation of atherosclerosis, arterial hy-
pertension, hypercholesterolemia, hypertriglyceridemia, dia-
betes mellitus, congestive heart failure, liver injury, chronic
kidney disease, smoking (current or more than 1 year in the
past), and a positive family history of cardiovascular diseases.
The criteria for each comorbidity were as follows: arterial
hypertension, a history of hypertension (blood pressure >
140/90 mmHg) or ongoing antihypertensive therapy; hyper-
cholesterolemia, a serum total cholesterol > 5.2 mmol/l or on-
going antihypercholesterolemic therapy; hypertriglyc-
eridemia, a serum triglycerides > 1.7 mmol/l; diabetes
mellitus, use of insulin or oral hypoglycemic agents or a
fasting serum glucose > 7.0 mmol/l; congestive heart failure,
left ventricular ejection fraction below 40%; liver injury, a
serum alanine aminotransferase elevated more than twice
above upper limit of the reference range; and chronic kidney
failure, an estimated glomerular filtration rate (eGFR) below
60 ml/min/1.73 m2.
Laboratory analysis
Fasting blood samples were drawn in the morning from the
antecubital vein with minimal tourniquet use. Routine labora-
tory techniques were used to measure lipid profile, glucose,
alanine transaminase, urine, creatinine for eGFR, and com-
plete blood count (including eosinophilia and platelet count).
C-reactive protein (CRP) was measured by the Johnson &
Johnson VITROS 250. Blood samples were drawn into serum
separation tubes, centrifuged at 2000×g for 10 min at room
temperature within 2 h of collection. The supernatant was
frozen in aliquots and stored at − 70 °C until analyzed. IL-6,
VCAM-1, and soluble thrombomodulin levels were measured
using standardized ELISA assay (R&D Systems,
Minneapolis, MN, USA). Antinuclear antibodies (ANA) and
ANCAwere analyzed in patients by indirect immunofluores-
cence tests (ThermoFisher, Waltham, USA). Sera with posi-
tive ANA or ANCA were further analyzed with antigen-
specific ELISA for autoantibodies against proteinase 3 (anti-
PR3 I gG ) , mye l o p e r o x i d a s e ( a n t i -MPO IgG )
(EUROIMMUN, Lübeck, Germany).
Spirometry
Spirometry was performed using a Jaeger Master Screen spi-
rometer on patients with EGPA according to the standards of
the American Thoracic Society.
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Ultrasound examinations
Ultrasound studies were performed in a darkened, quiet
room with subjects resting in a supine position for 10 min
prior and fasting for 10 h. Examinations were conducted
by two independent ultrasound experts using the Siemens
Acuson Sequoia 512 with a 10-MHz linear array ultrason-
ic transducer (MountainView, CA, USA). Both experts
made three consecutive measurements of each parameter
(described below). The value used for each parameter was
the mean of the six measurements. In addition, a transtho-
racic echocardiogram (TTE) was performed for every par-
ticipant with measurements of left ventricular ejection
fraction (EF) and of systolic pulmonary artery pressure
using standard methods [17].
Brachial artery ultrasonography
Flow-mediated dilatation (FMD) of the brachial artery
was measured using Celermayer’s method [18]. A base-
line sagittal diameter (D1) of a distal part of the brachi-
al artery was measured in the M-presentation by using a
10-MHz linear array ultrasonic transducer placed 2–
3 cm proximal to the arterial bifurcation. A sphygmo-
manometer cuff was then placed on the forearm below
the elbow and inflated to a pressure of 200 mmHg for
5 min and released. One minute after releasing the cuff,
the brachial artery diameter was measured again (D2) at
the same point. FMD was defined as the increase of
brachial artery diameter after deflation of the cuff and
was expressed as a percentage of the baseline diameter
(FMD% = [(D2 −D1) D1] × 100%).
Intima-media thickness of the common carotid artery
The intima-media thickness (IMT) of the carotid artery was
measured by ultrasound with a 10-MHz linear transducer. The
thickness of the anterior and posterior walls of common ca-
rotid arteries was measured bilaterally in the longitudinal pro-
jection immediately proximal to their bifurcation. The mean
value of the right and left thicknesses was used in further
analysis.
Statistical analysis
The results of the EGPA and control groups were compared
using STATISTICA 12.5 software. The continuous variables
were all non-normally distributed according to the Shapiro-
Wilk test. They are reported here as median and interquartile
range and compared using the Mann-Whitney U test.
Categorical variables are reported as percentages and com-
pared by χ2 test. Potential confounders are age, sex, BMI,
and comorbidities, such as arterial hypertension, diabetes
mellitus, and hypercholesterolemia. To adjust for these, the
results of FMD%, IMT, VCAM-1, and thrombomodulin were
log-transformed and a one-way covariance analysis
(ANCOVA) was performed, first with an adjustment for age,
sex, and BMI and subsequently to comorbidities. The univar-
iate linear regression models with adjustment for BMI, age,
and sex were used to analyze associations between two select-
ed parameters. Unconditional multivariate logistic regression
was performed to calculate odds ratios (ORs) with 95% con-
fidence intervals (CIs). The cut-off values for VCAM-1,
FMD%, and thrombomodulin were determined by receiver
operating characteristic (ROC) curves. Determinants of
FMD% were assessed using simple regression models.
Results were considered statistically significant when the p
value was less than 0.05.
Results
Characteristics of patients and controls
Demographic and laboratory characteristics of patients
with EGPA and controls are presented in Table 1. Both
groups were similar in age, sex, and BMI. Patients with
EGPA had higher eosinophilia and inflammatory markers,
such us white blood cells, CRP, and IL-6. They had also
higher triglycerides level, while healthy individuals had
increased low-density lipoprotein. The remaining basic
laboratory parameters were comparable between both an-
alyzed groups. In TTE, subjects with EGPA had lower
ejection fraction; the values of the remaining parameters
were similar in patients and controls (Table 1).
In Table 2, we have shown parameters determining charac-
terization of the EGPA at the time of evaluation. The median
duration of the disease was 4.5 years (range 3–8) and all the
patients were in remission. Almost all of the subjects were
diagnosed with asthma (96.7%, n = 29), with low to mod-
erate bronchial obstruction in spirometry. Inflammation of
the paranasal sinuses was found in 24 (80%) subjects and
nasal polyps in 14 (46.7%). Heart involvement was doc-
umented in 66.7% (n = 20) of patients, 13 (43.3%) had
lung infiltrates, and the same number was diagnosed with
peripheral nerve damage.
Positive ANCA were detected in 53.3% of patients (n =
16), ANA in 33.3% (n = 10), and anti-MPO in 23.3% (n =
7), while anti-PR3 was present only in one subject.
Among patients with EGPA, 86.7% (n = 26) were currently
being treated with corticosteroids (at a median dose equivalent
to 8 mg/day of methylprednisolone, range 4–16). They also
received immunosuppressive therapy in the past: azathioprine
(30%, n = 9), cyclophosphamide (43.3%, n = 13), methotrex-
ate (16.7%, n = 5), and mycophenolate mofetil or rituximab
(both 3.3%, n = 1). Comorbidities in EGPA patients
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included arterial hypertension (23.3%, n = 7), diabetes
mellitus (10%, n = 3), and hypercholesterolemia (26.7%,
n = 8) (Table 2). Angiotensin-converting enzyme inhibi-
tors or angiotensin receptor antagonists were taken by
36.7% of patients (n = 11), beta-blockers and diuretics
by 26.7% (n = 8), and statins by 20% (n = 6), while calci-
um channel blockers were used in 13.3% (n = 4) of sub-
jects. Ten subjects (33%) were ex-smokers.
Laboratory markers of endothelial injury
Patients with EGPA had a 20% higher serum level of VCAM-
1 and a 41.9% of thrombomodulin compared to healthy indi-
viduals (both p < 0.001). In ANCOVA analysis, we demon-
strated that both these markers remained increased in EGPA
subjects also after adjustment for potential confounders (age,
sex, BMI, hypercholesterolemia, hypertension, and diabetes






Patients, na = 30 Controls, n = 58 p value
Age (years) 49 (44–58) 47.5 (40.5–58.5) 0.63
Male gender, number (%) 10 (33.3) 24 (41.4) 0.36
Female gender, number (%) 20 (66.6) 34 (58.8) 0.72
Body mass index (kg/m2) 24.9 (21.2–27.5) 26.6 (23.9–29.1) 0.1
Basic laboratory tests
Hemoglobin (g/dl) 13.4 (12.3–14.7) 13.7 (12.7–15) 0.42
Red blood cells (106/μl) 4.5 (4.1–5.0) 4.5 (4.2–4.9) 0.67
White blood cells (103/μl) 8.6 (6.96–13.1) 5.9 (5.03–6.96) 0 < 001*
Blood eosinophilia (103/μl) 0.3 (0.1–0.9) 0.1 (0.09–0.2) 0.02*
Blood platelet count (103/μl) 242 (187–327) 225 (200–275) 0.36
Total cholesterol (mmol/l) 5.4 (4.3–6) 4.9 (4.2–5.3) 0.12
Low-density lipoprotein (mmol/l) 2.5 (2.3–3.1) 3.1 (2.5–3.6) 0.02*
Triglycerides (mmol/l) 1.4 (1.1–2.1) 1.1 (0.7–1.5) 0.01*
Glucose (mmol/l) 4.7 (4.1–5.1) 4.95 (4.7–5.2) 0.07
Creatinine (mmol/l) 71.2 (59–81) 76.1 (68.3–90) 0.06
Urea (mmol/l) 5.3 (3.93–6.3) 4.6 (3.9–5.3) 0.15
Estimated glomerular filtration rate
(ml/min/1.73 m2)
81 (60–102.5) 60 (60–80) 0.03*
Alanine transaminase (IU/l) 26 (21–34) 22.5 (14–28) 0.05
C-reactive protein (mg/dl) 5 (1.7–11.1) 1.2 (1–2.1) 0 < 001*
Interleukin-6 (pg/ml) 4.5 (1.7–9.4) 1.7 (1.1–2.2) 0 < 001*
Echocardiographic parameters
Left ventricular diastolic diameter (cm) 4.7 (4.4–4.9) 4.7 (4.5–4.9) 0.43
Left ventricular systolic diameter (cm) 3 (2.9–3.2) 3 (2.9–3.1) 0.55
Right ventricular diameter (cm) 2.1 (2–2.3) 2.1 (1.9–2.3) 0.42
Left atrial diameter (cm) 3.7 (3.4–3.8) 3.7 (3.5–3.9) 0.43
Left ventricle posterior wall thickness (cm) 1 (0.9–1) 0.9 (0.8–1) 0.19
Interventricular septum thickness (cm) 1 (0.9–1.1) 0.9 (0.8–1) 0.15
Ejection fraction (%) 62.5 (50–68) 68 (68–70) 0 < 001*
Pulmonary artery pressure (mmHg) 33 (30–36) 32 (26–32) 0.06
Laboratory parameters of endothelial injury
Vascular cell adhesion molecule-1 (ng/ml) 966.1 (845.8–1129.5) 804.6 (694.4–936.7) 0 < 001*
Thrombomodulin (ng/ml) 6.1 (5.2–6.5) 4.3 (3.9–4.7) 0 < 001*
Ultrasound parameters of endothelial injury and atherosclerosis
Relative increase of flow-mediated dilatation
of a brachial artery (%)
6.3 (5.3–8.8) 10.3 (8.9–12.5) 0 < 001*
Median value of intima-media thickness of
a common carotid artery (cm)
0.07 (0.06–0.08) 0.07 (0.06–0.08) 0.24
Categorical variables are presented as numbers (percentages) and continuous variables as median and interquartile
range. The results which are statistically significant are marked *
a n number
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mellitus) (both, p < 0.001). EGPA subjects were characterized
by a 2.63 [95% CI 1.13–5.17] increased risk of elevated
VCAM-1 and a 4.68 [95% CI 2.3–9.5] risk of higher
thrombomodulin, as compared to the controls (cut-off points
837.6 ng/ml and 5.2 ng/ml, respectively). Interestingly, both
endothelial injury parameters were negatively associated with
the duration of the disease (β = − 0.66 [95% CI − 0.9 to −
0.41], β = − 0.43 [95% CI − 0.79 to − 0.07] VCAM-1 and
thrombomodulin, respectively).
The level of thrombomodulin, but not VCAM-1, was posi-
tively related to the inflammatory markers, such as IL-6 (β =
0.52 [95%CI 0.17–0.87]), CRP (β = 0.58 [95%CI 0.17–0.99]),
and white blood cell count (β = 0.39 [95% CI 0.06–0.72]). We
found positive associations between VCAM-1 and urea or cre-
atinine blood levels (β = 0.49 [95% CI 0.21–0.77] and β = 0.36
[95%CI 0.07–0.65], respectively).We also documented similar
relationships for thrombomodulin (β = 0.39 [95% CI 0.04–
0.74], β = 0.69 [95% CI 0.41–0.97], urea and creatinine blood
Table 2 Clinical characteristics




Duration of the disease (years) 4.5 (3–8)
Antinuclear antibodies presence, na(%) 10 (33.3)
Anti-neutrophil cytoplasmic antibodies presence, n (%) 16 (53.3)
Anti-proteinase 3 IgG presence, n (%) 1 (3.33)
Anti-myeloperoxidase IgG presence (%) 7 (23.3)
Organ involvement
Asthma, n (%) 29 (96.7)
Cutaneous vasculitis, n (%) 7 (23.3)
Granulomatous lesions in ears/hearing disturbances, n (%) 1 (3.3)
Nasal polyps, n (%) 14 (46.7)
Paranasal sinuses inflammation, n (%) 24 (80)
Bone destruction of paranasal sinuses, n (%) 7 (23.3)
Chronic kidney disease, n (%) 2 (6.7)
Lungs infiltrates, n (%) 13 (43.3)
Peripheral nerves damage, n (%) 13 (43.3)
Gastrointestinal symptoms, n (%) 6 (20.0)
Heart involvement, n (%) 20 (66.7)
Comorbidities
Hypertension, n (%) 7 (23.3)
Diabetes mellitus, n (%) 3 (10.0)






Currently, n (%) 2 (6.7)
In the past, n (%) 10 (33.3)
Smoking (packs/years) 0 (0–2.5)
Treatment characteristic
Current steroids, n (%) 26 (86.7)
Current corticosteroid dose, mg per day, recalculated to methylprednisolone 8 (4–16)
Systemic steroids therapy (years) 4 (2–6)
Immunosuppressive treatment (in the past)
Azathioprine, n (%) 9 (30.0)
Cyclophosphamide, n (%) 13 (43.3)
Methotrexate, n (%) 5 (16.7)
Mycophenolate mofetil, n (%) 1 (3.3)
Rituximab, n (%) 1 (3.3)
Internal medicine medications
Angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists, n (%) 11 (36.7)
Statins, n (%) 6 (20.0)
Beta-blockers, n (%) 8 (26.7)
Diuretics, n (%) 8 (26.7)
Calcium channel blockers, n (%) 4 (13.3)
Categorical variables are presented as numbers (percentages) and continuous variables as median and interquartile
range
a n number
bFEV1% forced expiratory volume in 1 s, percentage of reference range
cVC% vital capacity, percentage of reference range
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levels, respectively). Additionally, VCAM-1 in patients with
EGPAwas related to the interventricular septum and posterior
wall thickness (β = 0.52 [95%CI 0.29–0.75], β = 0.63 [95%CI
0.42–0.84], respectively). Comorbidities, medications, and type
of immunosuppressive treatment in the past had no impact on
laboratory markers of endothelial damage in the EGPA group
after comparison in subgroups.
Ultrasound parameters of endothelial injury
The EGPA group was characterized by a 38.8% decrease in
FMD%, compared to the control group (p < 0.001), also after
adjustment for potential confounders (age, sex, BMI, hyper-
cholesterolemia, hypertension, and diabetes mellitus), and
higher risk of diminished FMD% defined as values below
the cut-off point of 8.51 (OR 3.8 [95% CI 2.2–6.56]).
FMD% was negatively associated with CRP level (β = − 0.5
[95% CI − 0.75 to − 0.25]) without associations with remain-
ing inflammatory markers. However, a simple regression
models showed that serum level of IL-6 (β = − 0.36 [95% CI
− 0.62 to − 0.1]) and thrombomodulin (β = − 0.34 [95% CI −
0.6 to − 0.08]) may be related to lower FMD% values. The
same relationship was found for pack-years of smoking (β =
− 0.3 [95% CI − 0.5 to − 0.1]).
Among patients with EGPA, a lower FMD%was observed
in those with polyneuropathy (5.7 [5.1–6.2] vs. 8.3 [6.3–9.5],
p = 0.01) without differences to the other subgroups regarding
comorbidities or clinical symptoms.
The IMT measurement was similar in the EGPA and con-
trol groups and it did not correlate with laboratory parameters
of endothelial injury.
Discussion
This study is the first to find that EGPA is characterized by
endothelial injury. We demonstrated that even when EGPA is
in remission, increased levels of thrombomodulin and
VCAM-1 are present in the blood, suggesting ongoing endo-
thelial damage. Moreover, laboratory markers of endothelial
injury were accompanied by functional abnormalities in vaso-
dilatation of the brachial artery without acceleration of athero-
sclerosis reflected by IMT values. We also found a positive
correlation between VCAM-1 and interventricular septum and
posterior wall thickness, which indicate general stiffness not
only of vessels but also of the heart structures. The evaluated
parameters of endothelial damage did not differ regardless of
comorbidities, medications, or immunosuppressive treatment
in the past, as it has been shown in statistical analyses per-
formed in this study.
Our findings are partly in the line with other studies regard-
ing endothelial injury in vasculitis. Schimtt et al. [19] demon-
strated that serum levels of thrombomodulin were
significantly elevated only during the active stage of EGPA
and correlated with disease activity. However, anti-endothelial
cell antibodies which may be one of the driving mechanisms
for vascular injury in AAV were detected in EGPA patients
regardless of the stage of the disease in their study. Sangle et
al. [12] confirmed accelerated atherosclerosis in AAV patients
(seven of them were EGPA subjects) by measurements of
ankle-brachial pressure index. In the other study, performed
by Chironi et al. [11], subclinical atherosclerosis was detected
by ultrasonic measurements of plaque in three peripheral ves-
sels (carotid and femoral arteries and abdominal aorta; in this
study 11 EGPA patients were enrolled).
Several explanations for the mechanism of endothelial inju-
ry in EGPA have been proposed. Activated eosinophils secrete
diverse pharmacologically active granule components with cy-
totoxic action capable of inducing damage of endothelial cells
[20]. Eosinophil activation can be assessed by the detection of
eosinophil cationic protein (ECP), major basic protein, and
eosinophil peroxidase. All may accumulate on endothelial sur-
faces and have a potent damaging effect, directly and indirectly
via the inhibition of the cell’s ability to support thrombin-
dependent activation of protein C [21]. It has also been shown
that ECP can bind to Hageman factor (coagulation factor XII)
in vitro and cause activation of the intrinsic coagulation path-
way [20]. Notably, in a retrospective study assessing the role of
eosinophils in thrombosis, 56% of patients with EGPA present-
ed in medical history with venous thrombosis, 38% with arte-
rial thrombosis, and 4%with mixed thrombosis [22]. In a study
by Kain et al. [23], over 90% of enrolled patients with autoim-
mune diseases had autoantibodies to lysosomal membrane
protein-2 that cause injury to endothelial cells in vitro. This
may explain ANCA negativity in some AAV patients. In
ANCA-positive subjects, the contact of neutrophils and
ANCAs with endothelium is considered to be the key event
in endothelial injury. In our study, the parameters of endothelial
injury did not differ in subgroups regarding presence of
ANCA, ANA, and anti-MPO antibodies (data not shown).
An alternative possibility for explanation endothelial injury
in EGPA is the influence of traditional cardiovascular risk
factors, including smoking and comorbidities, such as arterial
hypertension, diabetes mellitus, and hypercholesterolemia.
Although in our study, the pack-year smoking history was
an important factor affecting diminished FMD%, it had no
impact on laboratory markers of endothelial injury.
Moreover, in our study, no comorbidity had any effect on
endothelial injury parameters. Chronic kidney failure is anoth-
er factor that is thought to lead to endothelial dysfunction in
EGPA as it does in other autoimmune diseases [24]. This
hypothesis is partly supported in our study, reflected by the
positive correlation between VCAM-1 and thrombomodulin
with the serum levels of creatinine and urea. However, only
7% of EGPA patients enrolled in our study had confirmed
chronic kidney disease. Moreover, the presence of this
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complication can be attributed to a manifestation of EGPA in
these patients and may not even be a separate comorbidity.
Another mechanism is the atherogenic effect of systemic
inflammation. This is suggested in our study by the inverse
associations of white blood cells, CRP, and IL-6 with labora-
tory parameters of endothelial damage in the overall popula-
tion of enrolled patients and controls (data not shown).
Because the duration of the disease was negatively related to
the CRP concentration (data not shown), we concluded that a
longer disease course that is well managed with corticoste-
roids and immunosuppressants is a less active disease in terms
of acute inflammation. This may explain our results of nega-
tive associations betweenVCAM-1, thrombomodulin, and the
duration of the disease. Other studies found that only the ac-
tive phase of vasculitis accelerates atherosclerosis and immu-
nosuppressive treatment is the best method to control not only
the disease but also to prevent endothelial injury [25, 26].
Gonzalez-Juanatey et al. [27] demonstrated significant im-
provement of FMD% 4 weeks after the onset of steroid ther-
apy. Interestingly, other authors have shown that immunosup-
pressive treatment, especially with cyclophosphamide and
azathioprine, directly injures endothelial cells [28, 29]. The
number of patients in our study was too small to allow reliable
subgroup analysis in terms of immunosuppressive treatment.
Additionally, the majority of our patients with EGPAwere also
treated with steroids. Prolonged steroid therapy is associated
with hypertension, diabetes mellitus, and change in the lipid
profile, all of which influence on the risk of cardiovascular
events. This is may be partially offset by the finding that
steroids also improve endothelial function [27].
Based on the aforementioned results, we conclude that im-
munosuppressive treatment is the best method to control acute
inflammation and prevent endothelial injury. However, even
in the remission phase of EGPA, patients undergo endothelial
injury and would therefore benefit from additional preventive
interventions such as aspirin or statins therapy.
Our study is limited by the small number of participants
due to the relative rarity of the disease, not allowing for the
recruitment of a sufficient number of patients. Our control
group was not well matched in terms of comorbidities but
we attempted to eliminate these confounding variables by an
adjustment for comorbidities (hypercholesterolemia, hyper-
tension, diabetes mellitus) during statistical analysis. FMD%
and IMT are subjective measurements. To reduce the effect of
inter-operator variability, we used the same two researchers to
perform all the measurements and we considered mean of
three subsequent measurements in a further analysis.
Conclusion
Patients with EGPA present with endothelial injury which is
mainly caused by the pathogenesis of the disease: the
damaging effect of eosinophils, anti-neutrophil antibodies,
and inflammation. Although the process is mainly active in
acute inflammation, patients in remission of the disease also
present with ongoing endothelial injury. Proper immunosup-
pressive treatment is the best method to prevent atherosclero-
sis and future cardiovascular events; however, the patients
may benefit from additional preventive interventions.
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